Drug Trial Radar · NCT06727864
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Kaohsiung Veterans General Hospital.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Taipei Veterans General Hospital, Taiwan; National Taiwan University Hospital; Chang Gung Memorial Hospital; Far Eastern Memorial Hospital; E-DA Hospital; Kaohsiung Medical University
- First posted
- Dec 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an endemic area for TB. The development of efficacious, safe, and shorter treatment regimens could significantly improve treatment completion rate and reduce transmission of TB. The current treatment guidelines for drug-susceptible TB from the World Health Organization (WHO), American Thoracic Society (ATS), United States Center for Diseases Control (U.S. CDC), Infectious Diseases Society of America (IDSA) and European Respiratory Society (ERS) include 2 months of isoniazid, rifampin, pyrazinamide and ethambutol (HREZ), followed by 4 months of isoniazid, rifampin, and ethambutol(HRE). The current treatment regimen requires 6 months of treatment, despite being highly efficacious, requires long duration of treatment. Adherence to treatment is the major barrier which poses a negative impact to TB control, and increased cost to both the patient and the public health system. Developing an efficacious, safe and short treatment regimen can significantly improve TB management and treatment success rates.
Conditions
- Pulmonary Tuberculosis
Interventions
4-month regimen (2HERZ/2HRE)Drug
4-month (2HERZ/2HRE)
6-month (2HERZ/4HRE)Drug
2 months of HREZ followed by 4 months of HR/HRE
Primary outcomes
What the sponsor says the trial is designed to measure.
- TB disease free survival at 12 months post-randomizationTime frame: 12 months
- TB disease free survival at 24 months post randomizationTime frame: 24 months
- Grade 3-5 adverse eventsTime frame: From enrollment to the end of treatment at 4 or 6 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan · Recruiting
Far Eastern Memorial Hospital
New Taipei City, Bangiao, Taiwan · Recruiting
Taichung Hospital
Taichung, West, Taiwan · Recruiting
E-DA Healthcare Group
Kaohsiung City, Yanchao, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.